Aitken ML - Search Results

1

A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease.

Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, McNamara SC, Gibson RL, Ramsey BW, Carter BJ, Reynolds TC. Aitken ML, et al. Hum Gene Ther. 2001 Oct 10;12(15):1907-16. doi: 10.1089/104303401753153956. Hum Gene Ther. 2001. PMID: 11589832 Clinical Trial.

2

Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study.

Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A. Aitken ML, et al. JAMA. 1992 Apr 8;267(14):1947-51. JAMA. 1992. PMID: 1548827 Clinical Trial.

3

Variable severity of pulmonary disease in adults with identical cystic fibrosis mutations.

Burke W, Aitken ML, Chen SH, Scott CR. Burke W, et al. Among authors: aitken ml. Chest. 1992 Aug;102(2):506-9. doi: 10.1378/chest.102.2.506. Chest. 1992. PMID: 1643940

4

Nontuberculous mycobacterial disease in adult cystic fibrosis patients.

Aitken ML, Burke W, McDonald G, Wallis C, Ramsey B, Nolan C. Aitken ML, et al. Chest. 1993 Apr;103(4):1096-9. doi: 10.1378/chest.103.4.1096. Chest. 1993. PMID: 8131446

5

Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.

Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Schidlow DV, et al. Ramsey BW, et al. Among authors: aitken ml. Am Rev Respir Dis. 1993 Jul;148(1):145-51. doi: 10.1164/ajrccm/148.1.145. Am Rev Respir Dis. 1993. PMID: 8317790 Clinical Trial.

6

Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis.

O'Sullivan TA, Wang JP, Unadkat JD, al-Habet SM, Trager WF, Smith AL, McNamara S, Aitken ML. O'Sullivan TA, et al. Among authors: aitken ml. Clin Pharmacol Ther. 1993 Sep;54(3):323-8. doi: 10.1038/clpt.1993.154. Clin Pharmacol Ther. 1993. PMID: 8375128

7

Cystic fibrosis.

Aitken ML, Fiel SB. Aitken ML, et al. Dis Mon. 1993 Jan;39(1):1-52. doi: 10.1016/0011-5029(93)90028-2. Dis Mon. 1993. PMID: 8422840 Review.

8

Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis.

Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP, Gibson RL, Launspach J, Moscicki RA, Richards SM, Standaert TA, et al. Zabner J, et al. Among authors: aitken ml. J Clin Invest. 1996 Mar 15;97(6):1504-11. doi: 10.1172/JCI118573. J Clin Invest. 1996. PMID: 8617884 Free PMC article. Clinical Trial.

9

Retroviral vectors efficiently transduce basal and secretory airway epithelial cells in vitro resulting in persistent gene expression in organotypic culture.

Halbert CL, Aitken ML, Miller AD. Halbert CL, et al. Among authors: aitken ml. Hum Gene Ther. 1996 Oct 1;7(15):1871-81. doi: 10.1089/hum.1996.7.15-1871. Hum Gene Ther. 1996. PMID: 8894679

10

Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.

Eisenberg JD, Aitken ML, Dorkin HL, Harwood IR, Ramsey BW, Schidlow DV, Wilmott RW, Wohl ME, Fuchs HJ, Christiansen DH, Smith AL. Eisenberg JD, et al. Among authors: aitken ml. J Pediatr. 1997 Jul;131(1 Pt 1):118-24. doi: 10.1016/s0022-3476(97)70134-3. J Pediatr. 1997. PMID: 9255202 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

191 results

Search Page

Filters